GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis
- First Posted Date
- 2015-12-24
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 220
- Registration Number
- NCT02639338
Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 42
- Registration Number
- NCT02626026
- Locations
- 🇺🇸
Lovelace Scientific Resources, Inc., Venice, Florida, United States
🇺🇸Center for Arthritis & Osteoporosis, Elizabethtown, Kentucky, United States
🇺🇸Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years
- Conditions
- Interventions
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 167
- Registration Number
- NCT02616783
- Locations
- 🇫🇷
Hopital Necker les Enfants Malades, Paris, France
🇧🇪University Hospital Gent, Ghent, Belgium
🇮🇹Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I
- First Posted Date
- 2015-11-26
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 66
- Registration Number
- NCT02616029
- Locations
- 🇮🇹
ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco, Milano, Italy
🇫🇷Hopital Sainte Marguerite - Hospital, Marseille, France
🇪🇸Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2020-03-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 111
- Registration Number
- NCT02613871
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 943
- Registration Number
- NCT02607800
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 416
- Registration Number
- NCT02607735
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
- Conditions
- Interventions
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 631
- Registration Number
- NCT02607930
- Locations
- 🇺🇸
Infectious Disease Specialists of Atlanta, Decatur, Georgia, United States
🇺🇸Prime healthcare services - St Michael's LLC d/b/a Saint Michael's medical center, Newark, New Jersey, United States
🇺🇸Augusta University, Augusta, Georgia, United States
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
- Conditions
- Interventions
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 657
- Registration Number
- NCT02607956
- Locations
- 🇬🇧
St George's Healthcare NHS Trust, London, United Kingdom
🇨🇦Sunnybrook Health Sciences Centre, Toronto, Canada
🇦🇺Prahran Market Clinic, Prahran, Victoria, Australia
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 31
- Registration Number
- NCT02607228